BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
IBI363: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Innovent Biologics (Suzhou) Co. Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | recruiting | 170 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06797297 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal | Melanoma | active not recruiting | 203 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07402070 IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer | Resectable Stage II-III Non-small Cell Lung Cancer | not yet recruiting | 10 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07124793 A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors | EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | not yet recruiting | 60 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.